Mitchell Finer

Mitchell Finer has over two decades of experience in the biotech industry. Mitchell is currently the Chairman of the Advisory Board at TCR² Therapeutics. Prior to that, they were the President Research and Development, Chief Scientific Officer, and Cofounder at ElevateBio. Mitchell also served as the CEO of LifeEDIT, where they developed novel RNA-guided nucleases for ex vivo and in vivo gene editing.

Before LifeEDIT, Mitchell was the Founder, Executive Chairman, and CEO of Oncorus, where they identified and developed innovative oncology therapeutics. Mitchell was also a Cofounder and Board Member at CODA Biotherapeutics, where they helped develop non-opiate, gene therapy-based analgesics for neuropathic pain disorders.

In addition to their work in the biotech industry, Mitchell has also served as an Executive Partner at MPM Capital and as a Board Member at Semma Therapeutics. Mitchell has also held the position of Chief Scientific Officer at bluebirdbio and Senior Vice President and Chief Development Officer at ViaCyte.

Most recently, Mitchell served as the CEO of Intracel Corp and Genteric. Mitchell is currently the Vice President of Research at Cell Genesys.

Mitchell Finer has a Ph.D. from Harvard University in Biochemistry and Molecular Biology, and a B.A. from the University of California, Berkeley in Biochemistry and Microbiology. Mitchell did their postdoctoral fellowship at the Whitehead Institute for Biomedical Research in Gene/Genetic Therapy from 1986-1989.